Pharmaceuticals

Viral Vector Manufacturing Market 2026–2030: Emerging Trends and Forecast Opportunities

February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the viral vector manufacturing market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Viral Vector Manufacturing Market in 2030?

The viral vector manufacturing market has experienced substantial growth in recent years. It is projected to expand from $8.26 billion in 2025 to $9.9 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 19.9%. Historically, the market’s expansion was driven by factors including limited manufacturing capacity, high production cost, reliance on traditional gene delivery methods, regulatory barriers, and fragmented supply chains.

The viral vector manufacturing market is projected to experience substantial expansion in the coming years, reaching a valuation of $21.31 billion by 2030, driven by a compound annual growth rate (CAGR) of 21.1%. This anticipated growth during the forecast period is primarily fueled by factors such as the increasing demand for gene and cell therapies, continuous advancements in viral vector technology, a rise in R&D investments, the expansion of contract manufacturing organizations, and the greater embrace of personalized medicine. Key trends anticipated for the forecast period encompass innovation in gene therapy, efforts to optimize viral vector safety, the development of scalable manufacturing processes, enhanced regulatory compliance, and sophisticated upstream and downstream processing techniques.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

What Drivers Are Influencing Production Trends In The Viral Vector Manufacturing Market?

The projected expansion of the viral vector manufacturing market is significantly influenced by the rising occurrence of cancer and infectious diseases. An infectious disease is defined as an ailment caused by a virus or its harmful substances, which can be transmitted to a vulnerable host through interaction with an affected individual, animal, or object. Cancer encompasses various conditions that arise when abnormal cells proliferate uncontrollably within any bodily organ or tissue, extending beyond their normal limits to penetrate adjacent organs and disseminate throughout the body. Viral vectors are utilized to generate tumor antigens, which are proteins found on tumor cells, thereby stimulating the body’s immune system to combat cancer. Furthermore, viral vectors have proven effective as vaccines against numerous infectious illnesses in both pre-clinical and clinical investigations. For example, data from July 2024 by the Australian Institute of Health and Welfare, an Australia-based government agency, indicated a rise in diagnosed cancer cases in Australia from 160,570 in 2022 to 164,694 in 2023. This demonstrates a significant yearly increase, underscoring the expanding incidence of cancer within the nation. Additionally, in August 2024, figures released by the UK Health Security Agency, a UK-based executive agency, revealed 368 measles cases in England in 2023. This represents an almost sevenfold surge compared to the 53 cases documented in 2022, with 44% of cases occurring in the West Midlands and 33% in London. Consequently, the escalating prevalence of cancer and infectious diseases is a key factor propelling the expansion of the viral vector manufacturing market.

Which Segments Are Gaining Traction In The Viral Vector Manufacturing Market?

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Other End Users

Subsegments:

1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26

2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others

3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others

4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others

5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

Which Competitive Trends Are Impacting The Structure Of The Viral Vector Manufacturing Market?

Major companies operating in the viral vector manufacturing market are focusing on developing advanced products, such as viral vector platforms specifically designed for viral vector production and manufacturing. These viral vector platforms are comprehensive systems tailored to efficiently produce and process viral vectors for applications like gene therapy and vaccine development. For instance, in May 2023, AGC Biologics, a US-based global biopharmaceutical contract development and manufacturing organization (CDMO), launched the BravoAAV and ProntoLVV platforms. These offerings were designed to provide flexible and accelerated vector development and manufacturing for cell and gene therapy programs, ensuring GMP product delivery within nine months, backed by a global regulatory and supply network and in-house plasmid DNA services. Utilizing custom processes, templated material approaches, and prequalified analytical methods, these platforms are significant contributors to the viral vector manufacturing market’s projected growth, reaching $5.5 billion by 2035, by meeting the increasing demand for efficient development and delivery of life-changing gene therapies and vaccines.

Who Are The Core Companies Influencing Trends In The Viral Vector Manufacturing Market?

Major companies operating in the viral vector manufacturing market are Sanofi S.A., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Which Regions Are Projected To Dominate The Viral Vector Manufacturing Market In The Coming Years?

North America was the largest region in the viral vector manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Viral Vector Manufacturing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12398&type=smp

Browse Through More Reports Similar to the Global Viral Vector Manufacturing Market 2026, By The Business Research Company

Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Viral And Non Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Oral Expectorant Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795